MCID: ADR041
MIFTS: 49

Adrenal Cortical Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Adenoma

MalaCards integrated aliases for Adrenal Cortical Adenoma:

Name: Adrenal Cortical Adenoma 12 15 71
Adrenocortical Adenoma 12 17
Adenoma Adrenocortical 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050891
UMLS 71 C0206667

Summaries for Adrenal Cortical Adenoma

Disease Ontology : 12 An adrenal adenoma that is a benign tumor of the adrenal cortex.

MalaCards based summary : Adrenal Cortical Adenoma, also known as adrenocortical adenoma, is related to adenoma and gynecomastia. An important gene associated with Adrenal Cortical Adenoma is SYP (Synaptophysin), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Aldosterone synthesis and secretion. The drugs glucocorticoids and Melanocyte-Stimulating Hormones have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and pituitary, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Wikipedia : 74 Adrenocortical adenoma is commonly described as a benign neoplasm emerging from the cells that comprise... more...

Related Diseases for Adrenal Cortical Adenoma

Diseases related to Adrenal Cortical Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 adenoma 30.6 SYP REN PRKAR1A POMC MEN1 CYP21A2
2 gynecomastia 30.6 POMC INHA CYP21A2
3 adrenogenital syndrome 30.4 SYP INHA CYP21A2
4 amenorrhea 30.3 POMC NR5A1 CYP17A1
5 conn's syndrome 30.3 SULT2A1 REN PRKAR1A POMC MEN1 MC2R
6 gangliocytoma 30.3 SYP POMC
7 adrenal adenoma 30.3 SULT2A1 REN PRKAR1A POMC MIR483 MEN1
8 appendix adenocarcinoma 30.2 SYP CHGA
9 hyperandrogenism 30.2 POMC IGF2 CYP21A2 CYP17A1 CYP11A1
10 hypokalemia 30.2 REN POMC CYP17A1 CYP11B1
11 pheochromocytoma 30.1 SYP REN POMC MEN1 IGF2 CHGA
12 multiple endocrine neoplasia 30.1 PRKAR1A POMC MEN1 CHGA
13 paraganglioma 30.0 SYP MEN1 CHGA
14 hyperparathyroidism 30.0 PRKAR1A MEN1 CHGA
15 hemangioma 30.0 SYP MEN1 IGF2 CHGA
16 meningioma, familial 30.0 SYP PRKAR1A MEN1 IGF2
17 parathyroid adenoma 29.9 PRKAR1A MEN1 CHGA
18 polycystic ovary syndrome 29.9 SULT2A1 IGF2 CYP21A2 CYP17A1 CYP11A1
19 beckwith-wiedemann syndrome 29.9 PRKAR1A MIR483 MEN1 IGF2
20 carcinoid syndrome 29.9 SYP MEN1 CHGA
21 pseudohermaphroditism 29.8 POMC NR5A1 CYP21A2 CYP17A1 CYP11A1
22 primary hyperparathyroidism 29.8 PRKAR1A POMC MEN1 CHGA
23 acromegaly 29.7 PRKAR1A POMC MEN1 IGF2
24 lipoid congenital adrenal hyperplasia 29.7 REN POMC NR5A1 MC2R CYP21A2 CYP17A1
25 leydig cell tumor 29.7 SYP NR5A1 INHA CYP21A2 CYP17A1 CYP11A1
26 pituitary adenoma, prolactin-secreting 29.7 PRKAR1A POMC NR5A1 MEN1 CHGA
27 multiple endocrine neoplasia, type i 29.6 SYP PRKAR1A POMC MIR483 MEN1 CHGA
28 gastrointestinal stromal tumor 29.5 SYP MEN1 IGF2 CHGA
29 primary pigmented nodular adrenocortical disease 29.4 SYP PRKAR1A POMC MIR483 MEN1 MC2R
30 hypertension, essential 29.4 REN POMC MIR483 MEN1 CYP17A1 CYP11B1
31 familial glucocorticoid deficiency 29.2 REN POMC NR5A1 MC2R CYP21A2 CYP17A1
32 carney complex variant 29.0 PRKAR1A POMC MLANA MIR483 MEN1 MC2R
33 adrenal cortical carcinoma 28.4 SYP SULT2A1 PRKAR1A POMC NR5A1 MIR483
34 adrenal carcinoma 27.6 SYP REN PRKAR1A POMC NR5A1 MLANA
35 adrenal gland pheochromocytoma 10.5
36 basophil adenoma 10.4 PRKAR1A POMC
37 abducens nerve disease 10.4 SYP POMC
38 cauda equina syndrome 10.4 SYP POMC
39 sarcomatoid transitional cell carcinoma 10.4 SYP MLANA
40 hypoaldosteronism 10.4 REN POMC
41 glomangiosarcoma 10.3 SYP MLANA
42 primary hepatic neuroendocrine carcinoma 10.3 SYP CHGA
43 esophageal neuroendocrine tumor 10.3 SYP CHGA
44 auditory system benign neoplasm 10.3 SYP CHGA
45 benign perivascular tumor 10.3 SYP MLANA
46 transsexualism 10.3 CYP21A2 CYP17A1
47 precocious puberty 10.3
48 small cell carcinoma of the bladder 10.3 SYP CHGA
49 auditory system cancer 10.3 SYP CHGA
50 acinar cell cystadenocarcinoma 10.3 SYP CHGA

Graphical network of the top 20 diseases related to Adrenal Cortical Adenoma:



Diseases related to Adrenal Cortical Adenoma

Symptoms & Phenotypes for Adrenal Cortical Adenoma

GenomeRNAi Phenotypes related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CHGA CYP11B1 CYP21A2 GIPR IGF2 MC2R

MGI Mouse Phenotypes related to Adrenal Cortical Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 CYP11A1 CYP11B1 CYP17A1 CYP21A2 IGF2 MC2R
2 cardiovascular system MP:0005385 10.1 CHGA CYP11A1 CYP11B1 CYP17A1 IGF2 INHA
3 endocrine/exocrine gland MP:0005379 10 CHGA CYP11A1 CYP11B1 GIPR IGF2 INHA
4 growth/size/body region MP:0005378 10 CHGA CYP11A1 CYP11B1 CYP17A1 CYP21A2 IGF2
5 homeostasis/metabolism MP:0005376 9.8 CHGA CYB5A CYP11A1 CYP11B1 CYP17A1 GIPR
6 mortality/aging MP:0010768 9.47 CHGA CYP11A1 CYP11B1 CYP17A1 CYP21A2 IGF2

Drugs & Therapeutics for Adrenal Cortical Adenoma

Drugs for Adrenal Cortical Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 glucocorticoids Phase 3
2 Melanocyte-Stimulating Hormones Phase 3
3 Adrenocorticotropic Hormone Phase 3
4 beta-Endorphin Phase 3
5 Anti-Inflammatory Agents Phase 2
6 Gastrointestinal Agents Phase 2
7 Antineoplastic Agents, Hormonal Phase 2
8 Antiemetics Phase 2
9
Dopamine Approved 51-61-6, 62-31-7 681
10
Ethanol Approved 64-17-5 702
11
Racepinephrine Approved 329-65-7 838
12
Epinephrine Approved, Vet_approved 51-43-4 5816
13 Nutmeg Approved
14
Prazosin Approved 19216-56-9 4893
15
Diltiazem Approved, Investigational 42399-41-7 39186
16
Amlodipine Approved 88150-42-9 2162
17
Angiotensin II Approved, Investigational 68521-88-0, 4474-91-3, 11128-99-7 172198
18
Spironolactone Approved 1952-01-7, 52-01-7 5833
19
Indapamide Approved 26807-65-8 3702
20
Bisoprolol Approved 66722-44-9 2405
21
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
22
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
23
Hydrocortisone acetate Approved, Vet_approved 50-03-3
24
Hydrocortisone Approved, Vet_approved 50-23-7 5754
25
Zinc Approved, Investigational 7440-66-6 32051
26 Hypoglycemic Agents
27 Insulin, Globin Zinc
28 insulin
29 Epinephryl borate
30 Mace
31 Antihypertensive Agents
32 Angiotensin-Converting Enzyme Inhibitors
33 Angiotensin Receptor Antagonists
34 Angiotensinogen
35 Giapreza
36 Adrenergic alpha-Agonists
37 Respiratory System Agents
38 Anti-Asthmatic Agents
39 Adrenergic beta-Agonists
40 Adrenergic Agents
41 Neurotransmitter Agents
42 Mydriatics
43 Adrenergic Agonists
44 Bronchodilator Agents
45 Sympathomimetics
46 Vasoconstrictor Agents
47 Hormone Antagonists
48 Hormones
49 Hydrocortisone hemisuccinate
50 Hydrocortisone 17-butyrate 21-propionate

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant Recruiting NCT04308590 Phase 3 relacorilant
2 A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212 Completed NCT02150213 Phase 2 BGG492
3 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
4 Laparoscopic Adrenalectomy Versus Radiofrequency Ablation for Aldosterone-producing Adenoma: a Prospective Randomized Controlled Trial Unknown status NCT02030587
5 Expression of D2-Like Dopamine Receptor of Human Aldosterone-Producing Adenoma and Its Role in Regulation of Aldosterone Secretion and Cell Proliferation Unknown status NCT00173446
6 Evaluation of the Diagnostic Utility of Serum Dexamethasone Measurements in the Overnight 1mg Dexamethasone Suppression Test in Patients Investigated for Cushing's Syndrome and Incidentalomas Unknown status NCT01504555
7 Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism: Evaluation of the Blood Pressure Control and of Its Safety. Completed NCT02756754
8 Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma: Myth or Reality? Completed NCT00768365
9 Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions on Cross-sectional Imaging (CT or MRI) Completed NCT04071561
10 Complex Cystic Benign Adrenal Incidentalomas Mimicking Non-adenomatous Masses; Rare Pathologies: Clinical Features and Outcomes. Case Series With Short Review of Literature. Completed NCT03739918
11 Is There Anything New in the Field of Large Adrenal Tumors ? Completed NCT03830593
12 Long-term Effects of Adrenalectomy on Metabolic Syndrome, Glucose Metabolism, Lipid Metabolism, and Bone Metabolism in Subclinical Cushing's Syndrome of Adrenal Incidentaloma Recruiting NCT01382420
13 Natural History of Benign Nonfunctioning Adrenal Tumors: 10 Year Follow-up Results Recruiting NCT04616703
14 Prevalence, Characteristics and Prognosis of Adrenal Incidentalomas in Chinese Adults: a Prospective Study Recruiting NCT04682938
15 Feasibility Study of RadioFrequency Endoscopic ABlation, With ULtrasound Guidance, as a Non-surgical, Adrenal Sparing Treatment for Aldosterone-producing Adenomas Recruiting NCT03405025
16 Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations (ITACA Study) Recruiting NCT04127552
17 Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas Recruiting NCT02364089 Standardized medical treatment of hypertension by SAHR
18 Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield Recruiting NCT02324647
19 Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue Active, not recruiting NCT01949714
20 Morbidity and Mortality in Patients With Adrenal Incidentalomas With and Without Autonomous Cortisol Secretion Active, not recruiting NCT03919734
21 A Prospective Cohort Study for Patients With Adrenal Diseases Enrolling by invitation NCT03474237
22 Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT) Not yet recruiting NCT04328181

Search NIH Clinical Center for Adrenal Cortical Adenoma

Genetic Tests for Adrenal Cortical Adenoma

Anatomical Context for Adrenal Cortical Adenoma

MalaCards organs/tissues related to Adrenal Cortical Adenoma:

40
Cortex, Adrenal Cortex, Pituitary, Adrenal Gland, Bone, Thyroid, Kidney

Publications for Adrenal Cortical Adenoma

Articles related to Adrenal Cortical Adenoma:

(show top 50) (show all 982)
# Title Authors PMID Year
1
Biallelic APC inactivation was responsible for functional adrenocortical adenoma in familial adenomatous polyposis with novel germline mutation of the APC gene: report of a case. 54 61
19684041 2009
2
Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). 61 54
18419788 2008
3
The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses. 61 54
18393131 2008
4
Unique association of non-functioning pheochromocytoma, ganglioneuroma, adrenal cortical adenoma, hepatic and vertebral hemangiomas in a patient with a new intronic variant in the VHL gene. 54 61
16483185 2005
5
Significance of inhibin in reproductive pathophysiology and current clinical applications. 54 61
15970011 2005
6
Myxoid adrenocortical adenoma with a pseudoglandular pattern. 54 61
15235911 2004
7
Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. 54 61
15287021 2004
8
Primary hyperparathyroidism associatiated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. 54 61
15168774 2004
9
[The expression of A103 and inhibin alpha in adrenocortical adenoma by high-throughput tissue microarray techniques]. 61 54
12910679 2003
10
Massive adrenocortical adenoma following long-term treatment of 21-hydroxylase deficiency. 61 54
11832743 2002
11
Immunoexpression of inhibin alpha-subunit in adrenal neoplasms. 61 54
11556749 2001
12
Expression of adrenocorticotropin receptor gene in adrenocortical adenomas from patients with Cushing syndrome: possible contribution for the autonomous production of cortisol. 54 61
11420487 2001
13
Food-dependent androgen and cortisol secretion by a gastric inhibitory polypeptide-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies. 61 54
11158012 2001
14
Virilizing adrenocortical adenoma: in vitro steroidogenesis, immunohistochemical studies of steroidogenic enzymes, and gene expression of corticotropin receptor. 54 61
10216530 1999
15
Gene expression and roles of angiotensin II type 1 and type 2 receptors in human adrenals. 54 61
9761377 1998
16
[Aberrant expression of the GIP (Gastric Inhibitory Polypeptide) receptor in an adrenal cortical adenoma responsible for a case of food-dependent Cushing's syndrome]. 61 54
10333644 1998
17
Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. 54 61
9249232 1997
18
Oestrogen producing adrenocortical adenoma: clinical, biochemical and immunohistochemical studies. 54 61
8977764 1996
19
Immunolocalization of dehydroepiandrosterone sulfotransferase in normal and pathologic human adrenal gland. 54 61
8751327 1995
20
Expression of a high molecular weight form of insulin-like growth factor II in a Beckwith-Wiedemann syndrome associated adrenocortical adenoma. 54 61
7621447 1995
21
In-vitro evidence for the regulation of 17,20-lyase activity by cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome. 54 61
8137519 1994
22
Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas. 61 54
8288710 1994
23
Disordered expression of adrenal steroidogenic P450 mRNAs in incidentally discovered nonfunctioning adrenal adenoma. 54 61
1535042 1992
24
Decreased levels of steroid 21-hydroxylase [P450(c21)] and its mRNA in an adrenocortical adenoma associated with 21-hydroxylase deficiency. 54 61
2101789 1990
25
Endocrine activity of the "silent" adrenocortical adenoma is uncovered by response to corticotropin-releasing hormone. 61 54
2165544 1990
26
Sum of High-Risk Gene Mutation (SHGM): A Novel Attempt to Assist Differential Diagnosis for Adrenocortical Carcinoma with Benign Adenoma, Based on Detection of Mutations of Nine Target Genes. 61
33564960 2021
27
Adrenocortical tumours in children: a review of surgical management at a tertiary care centre. 61
33438328 2021
28
Case Report on Anastomosing Haemangioma: An Unusual Vascular Tumor in Kidney. 61
33505742 2021
29
Black adrenal adenoma causing subclinical Cushing's syndrome complicated with pheochromocytoma. 61
33426500 2021
30
Primary Pancreatic Candidiasis Mimicking Pancreatic Cancer in an Immunocompetent Patient. 61
33495432 2021
31
Pyoderma Gangrenosum Occurring in the Setting of Hypercortisolism Associated With Adrenocortical Adenoma: A Pathophysiological Paradox. 61
33400420 2021
32
Expression of Glutamine Metabolism-Related and Amino Acid Transporter Proteins in Adrenal Cortical Neoplasms and Pheochromocytomas. 61
33505538 2021
33
Haemodynamics of primary aldosteronism associated with adrenocortical adenoma: insights from bioimpedance cardiography measurements. 61
32533871 2021
34
A case of behavioral changes in a castrated male cat due to a functional adrenocortical adenoma producing testosterone and androstenedione. 61
33489305 2021
35
Assessment of non-traumatic vertebral fractures in Cushing's syndrome patients. 61
33420960 2021
36
Novel Use of Feminization Laryngoplasty. 61
33500201 2021
37
Predicting malignancy in patients with adrenal tumors using 18 F-FDG-PET/CT SUVmax. 61
32914407 2020
38
Dopamine secreting adrenal tumor-ganglioneuroma rather than pheochromocytoma: case report. 61
33447572 2020
39
[A case of Endocrine Active Retroperitoneal Ganglioneuroma, Difficult to Differentiate From Adrenal Pheochromocytoma]. 61
33435654 2020
40
Cushing syndrome with acute kidney injury due to ureteral stones in a 6-year-old boy. 61
32871646 2020
41
A Critical Analysis of Computed Tomography Washout in Lipid-Poor Adrenal Incidentalomas. 61
33210268 2020
42
Utility of contrast-enhanced ultrasound in differential diagnosis of adrenal tumors in dogs. 61
32968037 2020
43
Letter to the Editor from Berthon: "Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenoma". 61
32808982 2020
44
Response to Letter to the Editor from Berthon: "Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patients With Cortisol-Secreting Adrenocortical Adenoma". 61
32810276 2020
45
Adrenal-Renal Fusion with Adrenal Cortical Adenoma and Ectopic Adrenal Tissue, Presenting as Suspected Renal Mass: A Case Report. 61
33224009 2020
46
Immunohistochemical Analysis of the Metabolic Phenotype of Adrenal Cortical Carcinoma. 61
32367334 2020
47
[EUROCRINE®: adrenal surgery 2015-2019- surprising initial results]. 61
32945919 2020
48
Adrenal Corticomedullary Mixed Tumor Associated With the FGFR4-G388R Variant. 61
32803097 2020
49
Inflammation in the neoplasms of the adrenal gland: Is there a prognostic role? An immunohistochemical study. 61
32825943 2020
50
Is primary aldosteronism a potential risk factor for aortic dissection? A case report and literature review. 61
32736558 2020

Variations for Adrenal Cortical Adenoma

Cosmic variations for Adrenal Cortical Adenoma:

9 (show top 50) (show all 118)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM86624499 RB1 pituitary,NS,adenoma,ACTH-FSH-GH-LH-PRL c.1861C>A p.R621S 13:48456250-48456250 3
2 COSM150337228 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
3 COSM151605250 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
4 COSM150962042 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 3
5 COSM151491351 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 3
6 COSM105887915 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
7 COSM110179104 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
8 COSM150547790 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
9 COSM150961028 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 3
10 COSM111910236 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
11 COSM102452270 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
12 COSM150526110 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
13 COSM151827775 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
14 COSM150088294 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 3
15 COSM102412283 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
16 COSM110181025 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
17 COSM150300123 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
18 COSM146902958 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
19 COSM150454007 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
20 COSM151356165 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 3
21 COSM150480970 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
22 COSM150141897 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
23 COSM151979920 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
24 COSM151836221 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
25 COSM111893529 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 3
26 COSM150660304 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
27 COSM146245709 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
28 COSM111894601 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 3
29 COSM150867955 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 3
30 COSM151353823 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 3
31 COSM111038093 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
32 COSM102485110 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
33 COSM151345590 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 3
34 COSM150868805 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 3
35 COSM151592258 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
36 COSM150274829 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
37 COSM102450402 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
38 COSM102380394 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
39 COSM150827985 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
40 COSM151559313 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.134C>A p.S45Y 3:41224646-41224646 3
41 COSM110212608 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
42 COSM150452305 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
43 COSM151343442 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.112T>C p.S38P 3:41224645-41224645 3
44 COSM151344333 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 3
45 COSM151570765 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.127G>C p.A43P 3:41224639-41224639 3
46 COSM149991639 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 3
47 COSM146867471 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3
48 COSM149959645 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH-alpha SU c.113C>A p.S38Y 3:41224646-41224646 3
49 COSM111917881 CTNNB1 pituitary,NS,adenoma,ACTH-FSH c.106G>C p.A36P 3:41224639-41224639 3
50 COSM151826992 CTNNB1 pituitary,NS,adenoma,ACTH-FSH-LH c.133T>C p.S45P 3:41224645-41224645 3

Expression for Adrenal Cortical Adenoma

Search GEO for disease gene expression data for Adrenal Cortical Adenoma.

Pathways for Adrenal Cortical Adenoma

Pathways related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 SULT2A1 POMC CYP21A2 CYP17A1 CYP11B1 CYP11A1
2
Show member pathways
12.33 POMC NR5A1 MEN1 MC2R CYP21A2 CYP17A1
3
Show member pathways
11.58 POMC MC2R CYP11A1
4 11.52 SULT2A1 POMC CYP21A2 CYP11B1 CYP11A1
5
Show member pathways
11.38 CYP21A2 CYP17A1 CYP11B1 CYP11A1
6
Show member pathways
11.31 SULT2A1 CYP17A1 CYP11B1
7
Show member pathways
10.92 POMC CYP21A2 CYP17A1 CYP11B1 CYP11A1
8
Show member pathways
10.82 CYP21A2 CYP17A1 CYP11B1

GO Terms for Adrenal Cortical Adenoma

Cellular components related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 8.8 CYP21A2 CYP17A1 CYB5A

Biological processes related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.71 SULT2A1 CYP21A2 CYP17A1 CYP11A1
2 male gonad development GO:0008584 9.65 REN NR5A1 INHA
3 cholesterol metabolic process GO:0008203 9.63 SULT2A1 CYP11B1 CYP11A1
4 sterol metabolic process GO:0016125 9.5 CYP21A2 CYP11B1 CYP11A1
5 regulation of blood pressure GO:0008217 9.46 REN POMC CYP11B1 CHGA
6 C21-steroid hormone biosynthetic process GO:0006700 9.43 CYP11B1 CYP11A1
7 cellular response to peptide hormone stimulus GO:0071375 9.43 MEN1 CYP11B1 CYP11A1
8 cortisol metabolic process GO:0034650 9.37 CYP11B1 CYP11A1
9 steroid biosynthetic process GO:0006694 9.26 CYP21A2 CYP17A1 CYP11B1 CYP11A1
10 glucocorticoid biosynthetic process GO:0006704 8.92 CYP21A2 CYP17A1 CYP11B1 CYP11A1

Molecular functions related to Adrenal Cortical Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.56 CYP21A2 CYP17A1 CYP11B1 CYP11A1
2 monooxygenase activity GO:0004497 9.46 CYP21A2 CYP17A1 CYP11B1 CYP11A1
3 insulin-like growth factor receptor binding GO:0005159 9.32 REN IGF2
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP21A2 CYP17A1 CYP11B1 CYP11A1
5 heme binding GO:0020037 9.02 CYP21A2 CYP17A1 CYP11B1 CYP11A1 CYB5A

Sources for Adrenal Cortical Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....